Pharmacokinetics of the antiviral agent β-L-3′-fluoro-2′, 3′-didehydro-2′,3′-dideoxycytidine in Rhesus Monkeys

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 560-564

  Asif, Ghazia ^a,c   Hurwitz, Selwyn J ^a,c   Gumina, Giuseppe ^d   Chu, Chung K ^d   McClure, Harold M ^b   Schinazi, Raymond F ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA L 3' FLUORO 2',3' DIDEHYDRO 2',3, DIDEOXYCYTIDINE; BICARBONATE; BUFFER; LAMIVUDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SYNTHESIS; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STEADY STATE;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BICARBONATES; BIOLOGICAL AVAILABILITY; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; MACACA MULATTA; REFERENCE STANDARDS; ZALCITABINE;

EID: 12944291457     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.560-564.2005     Document Type: Article

References (32)

1. Blum, H. E., L. Stowring, A. Figus, C. K. Montgomery, A. T. Haase, and G. N. Vyas. 1983. Detection of hepatitis B DNA in hepatocytes, bileduct epithelium and vascular elements by in situ hybridization. Proc. Natl. Acad. Sci. USA 80:6685-6688.
2. Boudinot, F. D., R. F. Schinazi, J. M. Gallo, H. M. McClure, D. C. Anderson, K. J. Doshi, P. C. Kambhimapathi, and C. K. Chu. 1990. 3′-Azido-2′,3′-dideoxyuridine (AzddU); comparative pharmacokinetics with 3′-azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res. Hum. Retrovir. 6:219-228.
3. Boudinot, F. D., R. F. Schinazi, K. J. Doshi, H. M. McClure, and C. K. Chu. 1993. Pharmacokinetics and metabolism of 3′-azido-2′,3′- dideoxy-5-methylcytidine in monkeys. Drug Metab. Dispos. 21:855-860.
4. Chen, H., S. B. Pai, S. J. Hurwitz, C. K. Chu, Y. Glazkova, H. M. McClure, M. Feitelson, and R. F. Schinazi. 2003. Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-β-L-glyceropent-2-enofuranosyl) cytosine. Antimicrob. Agents Chemother. 47:1922-1928.
5. Chong, Y., G. Gumina, J. S. Mathew, R. F. Schinazi, and C. K. Chu. 2003. L-2′,3′-didehydro-2′,3′-dideoxy-3′- fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. J. Med. Chem. 46:3245-3256.
6. Chong, Y., L. Stuyver, M. J. Otto, R. F. Schinazi, and C. K. Chu. 2004. Mechanism of antiviral activities of 3′-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modeling approach. Antivir. Chem. Chemother. 14:309-319.
7. De Clercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-169.
8. Delaney, W. E., I. V. Slocarnini, and L. Shaw. 2001. Resistance to hepatitis B virus to antiviral drugs: current aspects and future investigation. Antivir. Chem. Chemother. 12:1-35.
9. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
10. Gabrielsson, J., and D. Weiner (ed.). 2000. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 3rd ed., p. 71-96, 273. Apotekarsocieteten, Stockholm, Sweden.
11. Gelmont, K., J. S. G. Montaner, M. Fanning, J. R. M. Smith, J. Falutz, C. Toukas, J. Gill, G. Wells, M. O'Shaughnessy, M. Wainberg, and J. Ruedy. 1989. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 3:555-561.
12. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 113-114. Marcel Dekker, Inc., New York, N.Y.
13. Gumina, G., R. F. Schinazi, and C. K. Chu. 2001. Synthesis and potent anti-HIV activity of 3′-fluoro-2′,3′-unsaturated cytidine. Org. Lett. 3:4177-4180.
14. Isel, C., C. Ehresmann, P. Walter, B. Ehresmann, and R. Marquet. 2001. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J. Biol. Chem. 276:48725-48732.
15. Lee, K., Y. Choi, E. Gullen, S. Schlueter-Wirtz, R. F. Schinazi, Y. Cheng, and C. K. Chu. 1999. Synthesis and anti-HIV and anti-HBV activities of 2′-fluoro-2′,3′-unsaturated L-nucleoside. J. Med. Chem. 42:1320-1328.
16. Ma, L., S. J. Hurwitz, J. Shi, J. J. Mcatee, D. C. Liotta, H. M. McClure, and R. F. Schinazi. 1999. Pharmacokinetics of the antiviral agent β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrob. Agents Chemother. 43:381-384.
17. Martin, L. T., E. Cretton-Scott, R. F. Schinazi, X-J. Zhou, H. M. McClure, C. Mathé, G. Gosselin, J.-L. Imbach, and J. P. Sommadossi. 1999. Pharmacokinetics of β-L-2′,3′-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrob. Agents Chemother. 43:920-924.
18. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
19. Qian, M., T. S. Finco, A. R. Swagler, and J. M. Gallo. 1991. Pharmacokinetics of 2′,3′-dideoxyinosine in monkeys. Antimicrob. Agents Chemother. 35:1247-1249.
20. Richman, D. D. 1993. HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 32:149-164.
21. Schinazi, R. F. 2002. Therapeutics and vaccines for HIV: thinking outside the trap. Int. Antivir. News 9:182-183.
22. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 8:65-91.
23. Schinazi, R. F., C. K. Chu, A. Peck, A. McMillan, R. Mathis, D. Cannon, L. S. Jeong, J. W. Beach, W. B. Choi, S. Yeola, and D. C. Liotta. 1992. Activities of the four optical isomers of 2′,3′-dideoxy-3′- thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:672-676.
24. Schinazi, R. F., F. D. Boudinot, K. J. Doshi, and H. M. McClure. 1990. Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rhesus monkeys. Antimicrob. Agents Chemother. 34:1214-1219.
25. Schinazi, R. F., L. Stuyver, S. Lostia, C. Bozeman, B. Korba, B. C. Tennant, H. McClure, K. Chun, M. J. Otto, C. K. Chu. 2003. β-L-3′- Fluoro-2′,3′-didehydro-2′,3′-dideoxycytidine has potent and selective anti-HBV activity against lamivudine-resistant virus, abstr. V 785, p. 497. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., ASM Press, Washington, D.C.
26. Shah, V. P., K. K. Midha, J. W. A. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17:1551-1557.
27. Shewach, D. S., D. C. Liotta, R. F. Schinazi. 1999. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 45:1540-1557.
28. Skoron, B. 1995. Biological effects and safety of stavudine; overview of phase I and phase II clinical trials. J. Infect. Dis. 171(Suppl. 2):S113-S117.
29. Solas, C., Y. F. Li, M. Y. Xie, J. P. Sammadossi, and X. J. Zhou. 1998. Intracellular nucleotides of (-)-2′,3′-deoxy-3′-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 42:2989-2995.
30. Stuyver, L. J., S. Lostia, M. Adams, J. S. Mathew, B. S. Pai, J. Grier, P. M. Tharnish, Y. Choi, Y. Chong, H. Choo, C. K. Chu, M. J. Otto, and R. F. Schinazi. 2002. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46:3854-3860.
31. Wood, M. 1991. Pharmacokinetic drug interactions in anaesthetic practice. Clin. Pharmacokinet. 21:285-307.
32. Zhou, W., G. Gumina, Y. Chong, J. Wang, R. F. Schinazi, C. K. Chu. 2004. Synthesis, structure-activity relationships, and drug resistance of beta-D-3′-fluoro-2′,3′-unsaturated nucleosides as anti-HIV Agents. J. Med. Chem. 47(13):3399-3408.